Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Eli Lilly remains the weight-loss market leader, with Q1 revenue up 56% year over year to $19.8 billion and EPS up 170% to $8.26, while Zepbound remains the best-selling obesity drug. Novo Nordisk is narrowing the gap with oral Wegovy, a high-dose Wegovy formulation, and a developing pipeline, but Lilly is still judged the better buy despite trading at 31.3x forward earnings versus Novo's 13x. The article is constructive on the anti-obesity market overall, but favors Eli Lilly on stronger growth, product leadership, and diversification.

Analysis

The market is treating this as a single-name winner-take-most story, but the more important second-order effect is that obesity is shifting from a pure volume race to a channel and formulation race. The winner is not just the company with the best efficacy profile, but the one that can convert physician comfort, payer coverage, and adherence into durable refill economics. That favors the incumbent with broader non-obesity cash flows because it can defend price, fund capacity, and absorb launch friction longer than a purer obesity play.

Novo’s newer oral and higher-dose options matter because they attack two constraints that often cap adoption: injection resistance and perceived tolerability. If oral adoption keeps compounding over the next 2-3 quarters, it narrows the gap faster than headline share gains suggest, since pills tend to broaden the addressable population before peak efficacy matters. The catch is that the market may be underestimating execution risk around switching behavior, payer step edits, and real-world persistence; those frictions usually show up after the initial prescription burst.

The biggest hidden beneficiary may be the broader supply chain: contract manufacturers, oral drug-device packaging, and cold-chain less exposed firms can gain even if the leader changes. On the flip side, smaller metabolic-drug aspirants are at risk of being structurally marginalized because payer formularies will increasingly anchor around only two or three clinically credible brands. That consolidation dynamic can accelerate over the next 12-18 months and compress the valuation of second-tier obesity names.

The contrarian read is that the valuation gap is not purely a quality discount; it is also embedding a probability that Lilly’s growth normalizes faster than the market expects. If any combination of supply expansion, payer pushback, or weaker-than-expected real-world persistence hits in the next two quarters, the premium multiple can de-rate quickly even if fundamentals remain strong. In contrast, Novo’s depressed multiple already prices in a lot of bad news, so the asymmetric setup is less about catching up in absolute leadership and more about mean reversion if the launch cadence holds.

Key Decisions for Investors

• Stay long LLY, but prefer call spreads over outright stock for the next 3-6 months: upside remains strongest, yet the multiple is vulnerable to any sign of demand normalization or reimbursement friction.
• Initiate a tactical long NVO position on weakness with a 6-12 month horizon: the setup is asymmetric if oral adoption and higher-dose Wegovy continue to ramp, with limited downside relative to its compressed valuation.
• Pair trade long LLY / short a basket of smaller obesity-exposed pharma names: the incumbent should keep taking share while the second-tier names face payer and efficacy hurdles; this expresses the consolidation thesis with cleaner relative-risk control.
• Watch for a 1-2 quarter inflection in prescription persistence and refill data; if early oral adoption is not converting to sustained use, reduce NVO exposure quickly because the market will punish launch disappointment faster than it rewards initial script volume.
• For event-driven traders, buy NVO upside via 6-9 month calls into the next catalyst cycle and finance with lower-strike calls/covered structure; risk/reward improves if the market is still extrapolating the recent selloff.